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SAMHD1 enhances nucleoside-
analogue efficacy against HIV-1 in 
myeloid cells
Paula Ordonez1, Simone Kunzelmann2, Harriet C. T. Groom3,†, Melvyn W. Yap1, 
Simon Weising4, Chris Meier4, Kate N. Bishop3, Ian A. Taylor5 & Jonathan P. Stoye1,6
SAMHD1 is an intracellular enzyme that specifically degrades deoxynucleoside triphosphates into 
component nucleoside and inorganic triphosphate. In myeloid-derived dendritic cells and macrophages 
as well as resting T-cells, SAMHD1 blocks HIV-1 infection through this dNTP triphosphohydrolase 
activity by reducing the cellular dNTP pool to a level that cannot support productive reverse 
transcription. We now show that, in addition to this direct effect on virus replication, manipulating 
cellular SAMHD1 activity can significantly enhance or decrease the anti-HIV-1 efficacy of nucleotide 
analogue reverse transcription inhibitors presumably as a result of modulating dNTP pools that 
compete for recruitment by viral polymerases. Further, a variety of other nucleotide-based analogues, 
not normally considered antiretrovirals, such as the anti-herpes drugs Aciclovir and Ganciclovir and the 
anti-cancer drug Clofarabine are now revealed as potent anti-HIV-1 agents, under conditions of low 
dNTPs. This in turn suggests novel uses for nucleotide analogues to inhibit HIV-1 in differentiated cells 
low in dNTPs.
Sterile α -motif/histidine-aspartate domain-containing protein 1 (SAMHD1) is an antiretroviral protein that 
restricts HIV-1 infection in non-cycling cells such as macrophages1, dendritic cells (DCs)2 and resting CD4+ 
T-cells3,4. Viruses from the HIV-2/SIVsmm and SIVrcm/SIVmnd-2 lineages encode the accessory protein Vpx that 
overcomes this restriction by directing SAMHD1 for proteasomal degradation1,2,5,6.
The prevailing hypothesis is that SAMHD1 restricts HIV-1 replication through its dNTP triphosphohydro-
lase activity by depleting the intracellular dNTP pool to levels that do not support viral reverse transcription7–10. 
More recently, it has been proposed that SAMHD1 nucleic acid binding and a nuclease activity might contribute 
to alternative mechanisms of restriction11–14. However, although measurements of nucleic acid binding support 
this notion14,15, variability in the in vitro measurements of nuclease activity appear inconsistent with this idea11,14. 
In contrast, the nature of the allosteric regulation of SAMHD1 triphosphohydrolase activity through nucleotide 
binding and tetramerisation has been extensively characterised both structurally10,16–19 and biochemically19–22.
SAMHD1 restriction activity is also regulated by phosphorylation. In cycling THP_1 cells that are relatively 
permissive to HIV-1 infection, SAMHD1 is largely phosphorylated by cyclin A2/CDK1 at Threonine 592. By 
contrast, T592 phosphorylation is reduced in differentiated THP-1 cells that are restrictive to HIV-1 infection23–25. 
In other cell types and primary macrophages, CDK2 has been proposed to be the kinase that phosphorylates 
SAMHD126,27 controlled by upstream regulation through the cyclin D3/CDK6 complex28,29. Moreover, CyclinL2 
has been proposed to be a negative regulator of SAMHD1 in macrophages30, whereas a cyclin D2/CDK4/p21 
complex has been proposed to be responsible for maintaining the non-phosphorylated form of SAMHD1 in 
GM-CSF derived macrophages31.
The rate of HIV-1 proviral synthesis is limited by the intracellular dNTP concentration32 and it can be acceler-
ated in non-dividing cells by elevating intracellular dNTP levels33. Although SAMHD1 reduces the dNTP pool in 
non-cycling cells thereby decreasing HIV-1 infection7–9, other reports showed that SAMHD1 depletion of dNTP 
levels in cells could also increase the susceptibility of HIV-1 to nucleoside reverse transcriptase inhibitors (NRTIs) 
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used in antiretroviral therapy, likely by decreasing the levels of dNTPs that can compete with chain terminators 
during proviral synthesis34–36.
Agents that modulate SAMHD1 function would have great value for studies of its anti-HIV effects. Since the 
triphosphohydrolase activity of SAMHD1 is regulated allosterically by nucleotide analogues whilst the efficacy of 
nucleotide analogues can be affected simultaneously by SAMHD1 activity, we used a combination of in vitro and 
cell-based assays to study the mutual effects of nucleotide analogues and SAMHD1 activity on HIV-1 replication.
We first used an in vitro enzyme-coupled assay to test the effect on SAMHD1 activity of the triphosphate deriv-
atives of a panel of FDA-approved nucleoside analogues widely used in antiviral and anticancer therapy, detailed 
in Table 1. Aciclovir (ACV) and Ganciclovir (GCV) are acyclic guanosine analogues used as anti-herpesvirus 
agents37–39. The halogenated adenosine analogue Clofarabine (CFB) is employed in anticancer therapy40,41. The 
NRTIs Stavudine (d4T)42,43, Didanosine (ddI)44 and Abacavir (ABC)45 are selective inhibitors of HIV-1 and HIV-2 
replication used in HIV/AIDS therapy46,47. We next tested whether the presence of SAMHD1 caused changes in 
the anti-HIV-1 efficacy of these nucleoside analogues in phorbol myristate acetate (PMA)-treated and untreated 
human monocytoid cell lines. We also compared the efficacy of nucleoside analogues in U937 cells expressing 
SAMHD1 or the catalytically inactive mutant HD206–7AA, and in THP-1 cells expressing endogenous SAMHD1 
or transduced with Vpx. Surprisingly, this analysis revealed anti-HIV-1 activities for ACV, GCV and CFB in addi-
tion to the NRTIs in PMA-treated cells; these were further enhanced in the presence of added SAMHD1.
Results
In vitro activity of nucleotide analogues. Since the triphosphohydrolase activity of SAMHD1 is alloster-
ically regulated by nucleotide analogues, and nucleotide analogues can also be hydrolysed by SAMHD1, we used 
a coupled-enzyme in vitro assay to assess their role as activators, substrates or inhibitors of SAMHD1. We evalu-
ated the triphosphate forms of the panel of nucleoside analogues detailed in Table 1 as well as dideoxyguanosine 
triphosphate (ddATP) and Carbovir triphosphate (CBV-TP) that are active antiretroviral agents produced after 
cellular conversion of ddI to ddATP48,49 and ABC to CBV-TP50,51. Our previous in vitro assays, demonstrated 
that Aciclovir triphosphate (ACV-TP) was a non-hydrolysable allosteric activator of SAMHD1 with comparable 
efficiency to GTP, Ganciclovir triphosphate (GCV-TP) was also non-hydrolysable but displayed no activation of 
SAMHD1 and Clofarabine triphosphate (CFB-TP) was a substrate hydrolysed by SAMHD1 at a rate comparable 
to natural dNTP substrates in the presence of the activator GTP21. Other studies have demonstrated SAMHD1 
has little or no hydrolytic activity against stavudine triphosphate (d4T-TP)35,36. Our data confirm this observation 
(Fig. 1A) and in addition demonstrate that d4T-TP is not a SAMHD1 inhibitor or activator (Fig. 1B,C). By con-
trast, didanosine triphosphate (ddI-TP) is hydrolysed by SAMHD1 even in the absence of GTP. In the presence 
of activating GTP, ddI-TP hydrolysis increases three-fold, to around six-fold slower than the TTP hydrolysis 
rate (Fig. 1A). In addition, ddI-TP activates SAMHD1 triphosphohydrolase activity, but to a much lesser degree 
than the natural activator, GTP (Fig. 1B) and displays no significant inhibitory effects (Fig. 1C). Quantification 
of ddI-TP hydrolysis data, demonstrates cooperativity with respect to ddI-TP concentration (Fig. 1D). Data are 
best fit with a Hill equation with parameters KS = 226 ± 12 μ M, n = 1.7 ± 0.1 and kcat = 0.24 ± 0.04 s−1. ddI-TP 
only weakly activates SAMHD1 and analysis of the ddI-TP concentration dependence of TTP hydrolysis 
(Fig. 1E) yields only lower estimates for the maximal rate and the ddI-TP concentration at half maximal activa-
tion, kmax > 0.1 s−1 and Ka > 300 μ M. By contrast, analysis of ddATP, the cellular active form of ddI, revealed no 
hydrolysis by SAMHD1, as has been shown previously34,35 and additionally there was no measurable activation or 
inhibition of SAMHD1 by ddATP (Fig. 1F–H). Examination of Abacavir triphosphate (ABC-TP) and Carbovir 
Nucleoside analoguea Generic name Therapeutic useb Base References
Antiherpesvirus
 ACV Aciclovir HSV-1, HSV-2 and VSV treatment, EBV and CMV prevention G (37, 38)
 GCV Ganciclovir Treatment of CMV infections G (39)
Anticancer
 CFB Clofarabine Treatment of ALL in children after failure. Ac (40, 41)
NRTIs
 D4T Stavudine HIV/AIDS therapy T (42, 43)
 ddI Didanosine
HIV/AIDS therapy
Hd
(44, 48, 49)
 ddAe Dideoxy A A
 ABC Abacavir
HIV/AIDS therapy
Φ f
(45, 50, 51)
 CBVg Carbovir G
Table 1.  Nucleoside analogues selected for this study. aACV: Acycloguanosine; GCV: 2′ -Nor-2′ - 
deoxyguanosine; CFB: 2-chloro-9-(2′ -Deoxy-2′ -fluoro-beta-D-arabinofuranosyl)adenine; d4T: 2′ ,3′ - 
didehydro-2′ ,3′ -dideoxythymidine; ddI: 2′ ,3′ -dideoxyinosine; ddA: 2,3′ -Dideoxyadenosine; ABC: (1S, 4R)-4-
[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol; CBV (1S, 4R)-4-[2-amino-6-
oxo-1,6-dihydro-9H-purin-9-yl]cyclopent-2-en-1-yl]methanol. bHSV-1: Herpes simplex virus type I; HSV-2: 
Herpes simplex virus type II; VSV: Varicella zoster virus; EBV: Epstein-Barr virus; CMV: Cytomegalovirus; 
ALL: Acute Lymphoblastic Leukaemia. c2-Chloro-adenine. dHypoxanthine. eCellular converted form of ddI. 
fNon-natural (2-amino-6-(cyclopropylamino)purine). gCellular converted active form of ABC.
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Figure 1. The effects of d4T-TP,ddI-TP,ddA-TP, ABC-TP and CBV-TP on SAMHD1 triphosphohydrolase 
activity. (A) Hydrolysis of 0.3 mM TTP, d4T-TP or ddI-TP in the absence (left) and presence (right) of 0.1 mM 
activator GTP. (B) Activation of SAMHD1 TTP hydrolysis. Triphosphohydrolase activity was measured with 
0.3 mM TTP substrate upon addition of 0.1 mM GTP, d4T-TP or ddI-TP as activators. (C) Inhibition of SAMHD1 
GTP-activated TTP hydrolysis. Triphosphohydrolase activity was measured with 0.3 mM TTP and 0.1 mM 
GTP activator alone and with addition of 0.3 mM dApNHpp positive control, d4T-TP or ddI-TP. Error bars are 
the standard error of the mean (SEM) of three independent measurements. (D) Concentration dependence of 
SAMHD1 ddI-TP hydrolysis in the presence of 0.2 mM GTP (saturating activator concentration). Nonlinear 
least squares fitting using a Hill equation gives the apparent binding constant KS = 226 ± 12 μ M, catalytic constant 
kcat = 0.24 ± 0.04 s−1 and the Hill coefficient n = 1.7 ± 0.1 (Mean ± SEM). (E) ddI-TP allosteric activation of 
TTP hydrolysis. Rates were determined for 1 mM TTP at varying dd-ITP concentration. Nonlinear least squares 
fitting gives only lower estimates for the maximal rate and the ddI-TP concentration at half maximal activation of 
kmax > 0.1 s−1 and Ka > 300 μ M. (F) Hydrolysis of 0.3 mM TTP, ABC-TP, CBV-TP and ddATP in the absence (left) 
and presence (right) of 0.1 mM activator GTP. (G) Activation of SAMHD1 TTP hydrolysis. Triphosphohydrolase 
activity was measured with 0.3 mM TTP substrate upon addition of 0.1 mM GTP, ABC-TP, CBV-TP or ddATP 
as activators. (H) Inhibition of SAMHD1 GTP-activated TTP hydrolysis. Triphosphohydrolase activity was 
measured with 0.3 mM TTP and 0.1 mM GTP activator alone and with addition of 0.3 mM dApNHpp positive 
control, ABC-TP, CBV-TP or ddATP. Error bars are the range of data from two independent measurements.
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triphosphate (CBV-TP) also showed they were not hydrolysed by SAMHD1 and neither ABC-TP nor CBV-TP 
displayed any activation or inhibition of SAMHD1 (Fig. 1F–H).
Anti-HIV-1 activities of nucleoside analogues. The anti-HIV-1 activities of the six selected 
nucleoside-analogues and non-nucleoside RT inhibitor (NVP) and integrase inhibitor (RAL) controls were eval-
uated in proliferating H9 and Jurkat T cell lines (Supplementary Table S1). As would be expected for T cell lines, 
the anti-herpesvirus agents ACV and GCV showed no anti-HIV-1 activity when tested at concentrations up to 
200 μ M. The anticancer drug CFB did have anti-HIV-1 activity with EC50 values of 0.094 and 0.663 μ M in H9 and 
Jurkat cells, respectively. The three NRTIs (d4T, ddI and ABC) showed anti-HIV-1 activities with EC50 values 
below 10 μ M; NVP and RAL inhibited HIV-1 at nanomolar concentrations (Supplementary Table S1).
By contrast, when the anti-HIV-1 effects of these compounds were assessed in undifferentiated (PMA−) and 
PMA-differentiated (PMA+) U937 and THP-1 lines a different pattern emerged (Table 2). Here, although the 
anti-herpesvirus agents ACV and GCV did not show anti-HIV-1 activity in PMA− cells (EC50 > 200 μ M), ACV 
showed an increased activity in PMA+ U937 cells (EC50 = 52.2 μ M), and both ACV and GCV had extremely 
significant activities in PMA+ THP-1 cells (EC50 0.657 and 0.367 μ M; p values < 0.0001) (Fig. 2A,B,D,E). The 
anti-HIV-1 activity of CFB also increased in PMA+ cells. In U937, the increase was 3-fold and in THP-1 cells 
the increase was highly significant at 44-fold (EC50 = 0.003 μ M) (Fig. 2C,F). Measurements of the established 
NRTIs also revealed increases of anti-HIV-1 activities in PMA+ cells, with the greatest effects observed in THP-1 
cells. Thus, ddI and ABC had greatly increased anti-HIV-1 activities in PMA+ cells, down to nanomolar EC50 in 
THP-1 cells (22- and 16-fold, respectively) (Table 2). By contrast, d4T had similar anti-HIV-1 activity in PMA+ 
and PMA− U937 cells, with only a small increased activity (2-fold) when comparing PMA+ to PMA− THP-1 
cells (Table 2). As might be expected, the NVP and RAL controls showed only minor, non-significant differences 
(p values > 0.005) in their activities in PMA− and PMA+ cells (Table 2).
Increased anti-HIV-1 activities of NRTIs have been reported previously in PMA+ treated THP-1 cells and 
monocyte-derived macrophages (MDM), where dNTP levels are reduced34–36. However, our observations reveal 
that compounds with no apparent anti-HIV-1 activity in T-cells or undifferentiated monocytoid cell lines (ACV 
and GCV) can display marked anti-HIV-1 effects in differentiated monocytoid cells. Moreover, this observa-
tion is particularly marked in the differentiated THP-1 cells where SAMHD1 is expressed in its highly active 
non-phosphorylated form24.
Cytotoxicity of nucleotide analogues. To compare the anti-HIV-1 activities and cytotoxic effects of the 
nucleoside analogues in T- and monocytoid cell lines, we determined the cytotoxic concentration (CC50) by flow 
cytometry and calculated the selectivity index (SI) for each compound (Supplementary Tables S1 and S2). With 
the exception of CFB, all nucleoside analogues displayed no toxicity in any of the cell lines when evaluated at 
concentrations up to 200 μ M (CC50 > 200 μ M). In T cells, where ACV and GCV showed no anti-HIV-1 activity 
they also did not exhibit any cytotoxic effect (CC50 > 200 μ M). The anti-HIV-1 activity of CFB in T cells was only 
observed at greater than cytotoxic concentrations (SI < 1). In contrast, NRTIs (d4T, ddI, ABC) showed SIs > 30 
(Supplementary Table S1).
In monocytoid U937 and THP-1 cells, SI values increased significantly upon differentiation 
(Supplementary Table S2). ACV showed SI values of > 4 and > 304 in PMA+ U937 and THP-1 cells, respectively. 
Similarly, the SI of GCV increased to > 545 in PMA+ THP-1 cells. As observed in T cells, the anti-HIV-1 activity 
of CFB in PMA− cells was only observed at greater than cytotoxic concentrations (SI < 1). However, upon dif-
ferentiation cytotoxicity was greatly decreased (CC50 > 1.6 μ M) resulting in SI values of > 43 and > 533 in PMA+ 
U937 and THP-1 cells, respectively. The NRTIs (d4T, ddI, ABC) did not show cytotoxicity (CC50 > 200 μ M) thus 
increasing the SIs, particularly in PMA+ THP-1 cells (Supplementary Table S2).
Effect of SAMHD1 on the anti-HIV-1 activity of nucleoside analogues. To test whether the 
anti-HIV-1 activities of the selected nucleoside analogues could be further increased through dNTP depletion 
Nucleoside 
analogue
EC50 (μM)a [95% CI]b
U937 THP1
PMA− PMA+ PMA− PMA+
ACV > 200 52.2 [49.5–54.9] > 200 0.657 [0.476–0.838]
GCV > 200 > 200 > 200 0.367 [0.322–0.412]
CFB 0.119 [0.101–0.137] 0.037 [0.012–0.061] 0.132 [0.055–0.210] 0.003 [0.002–0.004]
d4T 6.55 [1.83–11.3] 7.04 [6.97–7.11] 6.21 [5.91–6.52] 3.95 [3.05–4.85]
ddI 45.8 [29.2–62.5] 2.45 [0.563–4.34] 2.03 [1.74–2.32] 0.093 [0.065–0.121]
ABC 14.1 [5.07–23.0] 7.47 [6.67–8.27] 0.493 [0.142–0.844] 0.031 [0.022–0.040]
NVP 0.505 [0.126–0.883] 0.118 [0.064–0.171] 0.369 [0.232–0.506] 0.219 [0.201–0.237]
RAL 0.013 [0.012–0.014] 0.063 [0.038–0.088] 0.044 [0.035–0.053] 0.037 [0.021–0.046]
Table 2.  Anti-HIV-1 activity of nucleoside analogues in monocytoid cell lines. aEC50 is the effective 
concentration of drug that inhibits infection of cells by 50% measured as percentage of GFP+ cells. Values were 
calculated by non-linear regression for at east two independent experiments. b95% confidence interval. Non-
ambiguous values were subject to a replicate test.
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by SAMHD1, we evaluated antiviral activities in undifferentiated (PMA−) and differentiated (PMA+) U937 cells 
transduced with catalytically active SAMHD1 (wt) or an inactive mutant (HD206-7AA). Comparative EC50 data 
and statistical significance test results from these assays are summarised in Table 3.
Inspection of these data showed that ACV and GCV had no anti-HIV-1 activity in PMA− cells transduced with 
either wt SAMHD1 or HD206-7AA. In PMA+ cells expressing HD206-7AA, ACV had anti-HIV-1 activity with 
EC50 = 50.9 μ M (Fig. 3A) comparable to that observed in untransduced U937 PMA+ cells (Fig. 2A). However, in 
PMA+ cells expressing wt SAMHD1, ACV anti-HIV-1 activity was enhanced a further 78 fold (EC50 = 0.652 μ M; 
p < 0.0001) (Fig. 3A). Similarly, GCV had no significant anti-HIV-1 activity in PMA+ cells expressing HD206-
7AA (EC50 > 200 μ M) but in cells expressing wt SAMHD1 anti-HIV-1 activity of GCV was also greatly enhanced, 
> 200 fold (EC50 = 0.876 μ M; p < 0.0001) (Fig. 3B). As was observed for endogenous SAMHD1 expression in 
THP-1 cells, these data demonstrate that exogenous expression of SAMHD1 in other differentiated monocytoid 
cells also greatly enhances the anti-HIV activities of ACV and GCV anti-herpesvirus agents.
Analysis of CFB data showed transduction of wt SAMHD1 or HD206-7AA did not affect the EC50 values of 
CFB in PMA− cells, which remained higher than the cytotoxic concentrations (Supplementary Table S2, SI < 1). 
Upon introduction of HD206-7AA into PMA+ U937 cells a small reduction in the CFB EC50 was observed 
(Fig. 3C) but only to a level comparable with untransduced PMA+ U937 cells (Table 2). In contrast, there was a 
22-fold increase in the anti-HIV-1 activity of CFB in PMA+ cells expressing wt SAMHD1 over those expressing 
HD206-7AA (Fig. 3C). Although, not as large as the effects observed with ACV and GCV these data demonstrate 
Figure 2. Anti-HIV-1 activities of ACV, GCV and CFB in monocytoid cell lines. PMA− (red) and PMA+ 
(blue) U937 (A–C) and THP-1 (D–F) cells were cultured in the presence of increasing concentration of 
Aciclovir (ACV) (A,D), Ganciclovir (GCV) (B,E) and Clofarabine (CFB) (C,F). Cells were incubated with 
HIV-1-GFP and the percentage of infected GFP+ cells, measured by flow cytometry. To account for differences 
in overall infectivity of PMA− and PMA+ cells, in each panel the data is plotted as the normalised percentage 
of GFP+ cells against drug concentration. Error bars represent the standard deviation from at least two 
independent experiments.
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that whilst differentiation of U937 cells alone reduces the EC50 of CFB to below cytotoxic levels, additional expres-
sion of SAMHD1 in differentiated monocytoid cells enhances the anti-HIV activity of CFB even further.
The NRTIs d4T and ddI showed only slightly greater anti-HIV-1 activities in PMA− cells expressing wt 
SAMHD1 over those transduced with HD206/7AA (3- and 2-fold, respectively) and ABC showed no significant 
difference (Table 3). In PMA+ HD206-7AA expressing cells the antiviral activities of all NRTIs (d4T, ddI and 
ABC) were increased but only to EC50 values comparable with those observed in untransduced cells (Table 2). 
However, in PMA+ cells expressing wt SAMHD1 the antiviral activities of all NRTIs (d4T, ddI and ABC) were 
increased significantly (11-, 81- and 41-fold, respectively) compared to cells expressing HD206-7AA (Fig. 3D–F). 
These data support the notion that SAMHD1 specifically enhances the efficacy of NRTIs through triphospho-
hydrolase activity acting on the cellular dNTP pool. This argument is strengthened further by the observations 
that the non-nucleoside RT inhibitor NVP and integrase inhibitor RAL did not show any significant difference in 
anti-HIV-1 activities upon wt SAMHD1 expression in PMA− or PMA+ cells (Table 3).
Vpx knockdown of SAMHD1 activity. Since we found significant differences in the anti-HIV-1 activities 
of nucleoside analogues in U937 cells expressing exogenous wt SAMHD1 or HD206-7AA, we further evaluated 
their anti-HIV-1 activities in undifferentiated (PMA−) and differentiated (PMA+) THP-1 cells expressing endog-
enous SAMHD1 after transduction with the HIV-2 accessory viral protein Vpx, which reduces SAMHD1 levels 
by targeting it for proteasomal degradation1,2,5,6. These data and statistical significance test results are summarised 
in Table 4.
No differences were observed in the anti-HIV-1 activities of ACV and GCV in PMA− THP-1 cells upon 
Vpx transduction (Table 4). By contrast, in PMA+ cells, transduction with Vpx reduced ACV anti-HIV-1 
activity 27-fold (p = 0.0004) (Fig. 4A) and GCV anti-HIV-1 activity was entirely lost (EC50 > 200 μ M), 
(p < 0.0001) (Fig. 4B). The anti-HIV-1 activity of CFB decreased in both PMA− and PMA+ THP-1 cells upon 
Vpx expression (Table 4). However, in the PMA− cells the EC50 was still greater than the observed CFB CC50 
(Supplementary Table S2). In PMA+ cells, introduction of Vpx reduced CFB anti-HIV-1 activity 4-fold (Fig. 4C). 
This maintained the EC50 at lower than cytotoxic levels but the reduction was significantly lower than that 
observed for ACV and GCV. Nevertheless, the data show that removal of SAMHD1 activity in differentiated 
THP-1 cells by Vpx-mediated proteasomal degradation results in reduction of anti-HIV-1 activity of these 
anti-herpes and anti-cancer agents.
Evaluation of the NRTIs showed that Vpx transduction of THP-1 PMA− cells resulted in only small effects 
on the anti-HIV-1 activities of d4T and ddI (2–3 fold lower) and no difference with ABC (Table 4). By contrast, 
in THP-1 PMA+ cells, the anti-HIV-1 activities of all NRTIs decreased significantly when cells were transduced 
with Vpx, d4T 35-fold, ddI 55-fold and ABC 187-fold (Fig. 4D–F). By comparison, Vpx transduction of PMA− or 
PMA+ THP-1 cells had no effect on anti-HIV-1 activities of control NVP and RAL (Table 4) suggesting that the 
decreased anti-HIV-1 activities of the NRTIs is a result of competition from an increased cellular dNTP pool 
following removal of SAMHD1.
Discussion
This study was initiated to identify nucleotide analogue drugs that would activate or inhibit SAMHD1 to facilitate 
an improved understanding of the effect of SAMHD1 on HIV-1 replication. To this end, we had two alternative 
but not mutually exclusive hypotheses. First that a drug affecting SAMHD1 activity, either positively or negatively, 
would impact dNTP pool sizes thereby affecting HIV-1 reverse transcription. Second, that cell dependent changes 
in SAMHD1 activity and the resulting changes in dNTP levels might influence the effects of the drugs themselves 
on HIV-1 replication. The data obtained and discussed below, provided clear evidence supporting the second 
hypothesis, at least in the majority of cases. This would suggest that altering SAMHD1 activity might provide a 
Nucleoside 
analogue
PMA− PMA+
EC50 (μM)a [95% CI]b
Fold pc
EC50 (μM) [95% CI]
Fold pSAMHD1 HD206/7AA SAMHD1 HD206/7AA
ACV > 200 > 200 — — 0.652 [0.175–1.13] 50.9 [46.1–55.8] 78 < 0.0001
GCV > 200 > 200 — — 0.876 [0.823–0.929] > 200 > 228 < 0.0001
CFB 0.138 [0.021–0.255] 0.108 [0.081–0.135] 1 0.0878† 0.0013 [0.000–0.002] 0.029 [0.022–0.036] 22 0.0010
d4T 0.801 [0.531–1.07] 2.71 [1.90–3.52] 3 0.0013 0.528 [0.317–0.739] 5.82 [5.671–5.969] 11 < 0.0001
ddI 23.7 [10.6–36.7] 55.1 [44.2–65.9] 2 0.0018 0.109 [0.030–0.188] 8.79 [7.53–10.1] 81 < 0.0001
ABC 17.5 [15.9–19.1] 22.1 [7.12–37.1] 1 0.0590† 0.173 [0.164–0.182] 7.06 [4.72–9.40] 41 < 0.0007
NVP 0.112 [0.000–0.223] 0.124 [0.000–0.248] 1 0.6442† 0.097 [0.000–0.195] 0.145 [0.113–0.177] 1 0.1297†
RAL 0.011 [0.002–0.020] 0.012 [0.003–0.021] 1 0.2115† 0.070 [0.013–0.127] 0.075 [0.007–0.143] 1 0.7548†
Table 3.  Anti-HIV-1 activity of nucleoside analogues in SAMHD1 expressing U937 cells. aEC50 is the 
effective concentration of drug that inhibits infection of cells by 50% measured as the percentage of GFP+ cells 
in SAMHD1+ or HD206/7AA+ populations. Values were calculated by non-linear regression for at least two 
independent experiments. b95% confidence interval. Non-ambiguous values were subject to a replicate test. 
cEC50 values for each replicate were used to perform an unpaired two-tailed t-test to determine differences 
between SAMHD1+ and HD206/7AA+ populations. †Difference not statistically significant.
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means for enhancing drug effectiveness. Surprisingly our data also provided unambiguous evidence for direct 
effects of ACV, GCV and CFB not normally thought of as antiretroviral drugs, on HIV-1 replication in certain 
non-proliferating cell types.
Control of dNTP pools in cycling and non-cycling cells. Cellular dNTP concentrations vary by a factor 
of at least 100 between rapidly proliferating cells typified by activated lymphocytes or tumour cells, where they are 
required by DNA polymerases to actively replicate the genome, and non-proliferating, terminally-differentiated 
cells such as monocyte-derived macrophages where they are important for DNA repair and mitochondrial DNA 
synthesis52–54. These levels are set by controlling the activity of the enzymes ribonucleotide reductase (RNR), cru-
cial for dNTP biosynthesis, and SAMHD1, that catalyses dNTP degradation55. Regulation of RNR and SAMHD1 
activity is provided by a range of mechanisms including synthesis, degradation, allostery and phosphorylation56–58 
that allow control of dNTPs at levels ranging from 20 nM to 2 μ M32. Given the requirement for dNTPs in HIV-1 
replication, such a range of concentrations might be expected to have profound effects both on the apparent 
efficiency of HIV-1 reverse transcription in different cell types as well as on interactions between RT and NRTIs.
In vitro measurements of SAMHD1 activity. It is possible that any concentration dependent drug effects 
on SAMHD1 activity might complicate interpretation of cell-based assays to examine nucleoside analogue effects 
on HIV-1 replication. Our in vitro experiments, summarized in Table 1 now allow us to exclude this possibil-
ity in the majority of cases. No evidence for SAMHD1 inhibition was seen with any analogue tested. Similarly 
Figure 3. Anti-HIV-1 activities of nucleoside analogues in U937 cells expressing SAMHD1. Antiviral 
activities were determined in undifferentiated (PMA−) and differentiated (PMA+) U937 cells expressing 
SAMHD1 or the mutant HD206-7AA. Cells were cultured in the presence of increasing concentration of 
Aciclovir (ACV) (A), Ganciclovir (GCV) (B), Clofarabine (CFB) (C), Stavudine (d4T) (D), Didanosine (ddI) 
(E) and Abacavir (ABC) (F). Cells were incubated with HIV-1-GFP and the percentage of infected GFP+ cells 
was measured by flow cytometry. PMA− cells expressing SAMHD1 (red filled circles), PMA+ cells expressing 
the mutant HD206-7AA (blue open circles) and PMA+ cells expressing SAMHD1 (blue filled circles) are 
shown. Infectivity data is plotted as the normalised percentage of GFP+ cells against drug concentrations. Error 
bars represent the standard deviation from at least 2 independent experiments.
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GCV-TP, d4T-TP, ABC-TP and CBV-TP showed no activity as activator or substrate, implying no direct effects 
on SAMHD1. By contrast both ACV-TP and ddI-TP were allosteric activators of SAMHD1 though ddI-TP was 
much less efficient than the natural activator GTP. Thus for these two compounds a role for activation cannot 
formally be excluded. However, ddI and ddI-MP are poor substrates for further phosphorylation by cellular 
kinases59 and ddI is rapidly metabolized to ddA-TP in cells49 making a direct effect of ddI-TP on SAMHD1 
activity unlikely.
Efficacy of NRTIs in cycling and non-cycling cells. NRTIs compete with endogenous dNTPs for incor-
poration into newly reverse transcribed HIV-1 DNA and act as chain terminators. Therefore, given equal cellular 
uptake and comparable conversion efficiency to triphosphorylated forms, their efficacy would be predicted to 
depend on the level of competing natural dNTPs. Thus in non-dividing cells further depletion of the dNTP pool 
by catalytically active SAMHD1 might be expected to profoundly reduce the doses of NRTIs required to inhibit 
HIV-1 infectivity. This notion is supported by our observations of increased NRTI efficacy in PMA-differentiated 
U937 cells transduced with active SAMHD1 (Table 3) and deceased NRTI efficacy in THP-1 cells were SAMHD1 
has been targeted for degradation through expression of Vpx (Table 4). In addition, although minor, the presence 
of SAMHD1 in proliferating myeloid cells results in enhancement of d4T and ddI anti-HIV-1 activity (Tables 3 
and 4).
Anti HIV-1 activity of CFB. Evaluation of our data also showed that SAMHD1 could enhance the 
anti-HIV-1 activity of the anticancer agent CFB (Tables 3 and 4). The anticancer agents 5-azacytidine, CFB, and 
resveratrol have previously been shown to exhibit potent anti-HIV-2 activity with EC50 values for 5-azacytidine, 
clofarabine and resveratrol being significantly lower for HIV-2 compared to HIV-160. More recently CFB was 
shown to have significant anti-HIV-1 activity in primary macrophages acting both to reduce dNTP concen-
trations by inhibiting RNR and HIV-1 viral DNA via RT61. Our data support these previous observations and 
also that concentration of CFB for full anti-HIV-1 activity was significantly decreased upon differentiation of 
monocytes (Table 2). Moreover, CFB anti-HIV-1 activity was enhanced 22-fold in the presence of SAMHD1 in 
PMA-differentiated monocytes (Table 3), consistent with a mechanism involving chain termination of HIV-1 
DNA synthesis in a manner analogous to NRTIs.
Anti HIV-1 activity of ACV and GCV. ACV and GCV are normally considered as herpes virus specific 
drugs. Their incorporation into growing DNA results in chain termination; selectivity is determined by the 
viral thymidine kinase, required for the efficient conversion into the mono and subsequent triphosphorylated 
derivatives needed for incorporation into DNA62. However they have also been shown to reduce HIV-1 load 
and/or delay disease progression63–65 with ACV acting as a chain terminator of reverse transcriptase66. If so, 
how does phosphorylation occur in HIV-1 infected individuals? One school of thought postulates that kinases 
from co-infecting human herpesviruses are involved67,68. Against this idea are studies that show that herpesvirus 
co-infection is not required for ACV activity against HIV-169 implying that as yet uncharacterised human kinases 
must be involved70.
Our data now show that SAMHD1 has a pronounced effect on the anti-HIV-1 activity of the drugs ACV and 
GCV when tested in myeloid derived cell lines. ACV and GCV do not display substantive anti-HIV-1 activities 
in proliferating monocytes (Table 2). However, in differentiated cells expressing SAMHD1, where the dNTP 
pool levels are much lower52,53,71 ACV and GCV anti-HIV-1 activities were greatly enhanced (Figs 2 and 3) and 
this enhancement could be abrogated by introduction of Vpx to reduce SAMHD1 triphosphohydrolase activity 
(Fig. 4). These data indicate that the anti-herpes virus drugs are most active in non-proliferating cells with low 
dNTP levels and are fully consistent with the observation that the anti-HIV-1 activity of ACV can be potentiated 
by ribavirin, a drug that depletes intracellular dGTP pools68 and that ACV can inhibit HIV-1 replication in rest-
ing T-cells69. Our observations also support the idea that a cellular kinase, expressed in THP-1 and U937 cells, is 
Nucleoside 
analogue
PMA− PMA+
EC50 (μM)a [95% CI]b
Fold pc
EC50 (μM) [95% CI]
Fold pVpx− Vpx+ Vpx− Vpx+
ACV > 200 > 200 — — 1.08 [0.735–1.43] 29.6 [2.62–56.5] 27 0.0004
GCV > 200 > 200 — — 0.632 [0.596–0.668] > 200 > 316 < 0.0001
CFB 0.340 [0.118–0.563] > 1.6 > 5 < 0.0001 0.003 [0.002–0.004] 0.012 [0.003–0.021] 4 0.0017
d4T 4.39 [3.76–5.02] 13.3 [12.1–14.4] 3 0.0001 1.49 [0.501–2.48] 52.2 [33.0–71.5] 35 0.0009
ddI 1.04 [0.863–1.22] 2.73 [1.40–4.07] 3 0.0039 0.079 [0.061–0.096] 4.34 [3.19–5.50] 55 0.0005
ABC 0.459 [0.399–0.519] 0.622 [0.356–0.888] 1 0.0619† 0.038 [0.036–0.040] 7.050 [4.67–9.43] 187 0.0002
NVP 0.244 [0.240–0.248] 0.292 [0.067–0.517] 1 0.1146† 0.223 [0.196–0.250] 0.235 [0.217–0.253] 1 0.0379†
RAL 0.035 [0.017–0.053] 0.043 [0.016–0.070] 1 0.0683† 0.038 [0.020–0.056] 0.037 [0.002–0.072] 1 0.9071†
Table 4.  Anti-HIV-1 activity of nucleoside analogues in Vpx expressing THP1 cells. aEC50 is the effective 
concentration of drug that inhibits infection of cells by 50% measured as the percentage of GFP+ cells in Vpx− 
or Vpx+ populations. Values were calculated by non-linear regression for at least two independent experiments. 
b95% confidence interval. Non-ambiguous values were subject to a replicate test. cEC50 values for each 
replicate were used to perform an unpaired two-tailed t-test to determine differences between Vpx− and Vpx+ 
populations. †Difference not statistically significant.
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responsible for initial phosphorylation. Such cells might provide starting material for the purification and further 
characterization of this enzyme.
In light of these results, the potential utility of nonstandard antiviral and anticancer drugs to target HIV-1 in 
differentiated cells low in dNTPs might also be considered. For example, our data, coupled with the low cost and 
favourable safety profile72 of ACV prompt the question of whether ACV might find a niche role in the treatment 
or prevention of HIV-1. Thus, it is tempting to speculate that ACV might be useful for the prevention of mother 
to child transmission, or for reducing reservoir size, in resource poor settings where viral load suppression of 
the expectant mother may be less than complete and treatment of the new-born infant could be initiated before 
results of tests for transmission become available. We are currently testing this idea in a variety of primary culture 
systems with low dNTP concentrations such monocyte-derived macrophages or resting T-cells, aiming to identify 
important HIV-1 target cells that are susceptible to ACV treatment.
Methods
Synthesis of abacavir-5′-triphosphate and carbovir-5′-triphosphate. The synthesis of the ammo-
nium salt of abacavir-5′ -triphosphate (ABC-TP) was performed as described73 with minor modifications. Under 
a nitrogen atmosphere 364 mg (1.27 mmol) of Abacavir was dissolved in 9.5 mL anhydrous pyridine and cooled 
to − 35 °C. Then 1.65 mL (1.65 mmol, 1.3 eq) of a 1 M solution of 5-chloro-cycloSaligenyl-phosphorchloridate in 
THF was added portion-wise over a period of 4 h. The reaction mixture was slowly warmed to room tempera-
ture and all volatiles were evaporated. The residue was co-evaporated three times with toluene (3 × 5 mL) and 
finally once with CH2Cl2. The crude product was purified by flash column chromatography (CH2Cl2/CH3OH + 1% 
Figure 4. Anti-HIV-1 activities of nucleoside analogues in differentiated THP-1 cells after Vpx knockdown 
of endogenous SAMHD1 expression. Antiviral activities were determined in differentiated (PMA+) THP-1 
cells expressing endogenous SAMHD1 and after transduction with Vpx. Cells were cultured in the presence of 
increasing concentrations of Aciclovir (ACV) (A), Ganciclovir (GCV) (B), Clofarabine (CFB) (C), Stavudine 
(d4T) (D), Didanosine (ddI) (E) and Abacavir (ABC) (F). Cells were incubated with HIV-1-GFP and the 
percentage of infected GFP+ cells was measured by flow cytometry. Cells expressing SAMHD1 (Vpx−) (blue 
filled circles), cells transduced with Vpx (Vpx+) (red filled circles) are shown. Infectivity data is plotted as the 
normalised percentage of GFP+ cells against drug concentrations. Error bars represent the standard deviation 
from at least 2 independent experiments.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7:42824 | DOI: 10.1038/srep42824
of acetic acid, 95:5 to 90:10) to give 490 mg of the cycloSaligenyl-triester with minor impurities. Then 47.5 mg 
(97.2 μ mol) of this phosphate triester were dissolved in 1 mL anhydrous DMF. A solution of 96.3 mg (146 μ mol) 
bis-tetrabutylammonium hydrogen pyrophosphate in 0.7 mL DMF, which had been stirred for 1 h over 4 Å molec-
ular sieves, was added in one aliquot. After 72 h the solvent was removed under reduced pressure and the residue 
was purified by reverse phase flash column chromatography (H2O/CH3CN, 99:1 to 0:100), ion exchange (NH4+) 
on Dowex (50WX8) and again reversed phase flash column chromatography (H2O/CH3CN, 100:1 to 0:100) to 
give 20.5 mg (34.5 μ mol) of the triphosphate as a colourless solid after freeze drying. 1H NMR: (600 MHz, D2O): 
δ [ppm] = 7.99 (s, 1H), 6.19–6.26 (m, 1H), 5.93–5.89 (m, 1H), 5.52–5.48 (m, 1H), 4.10–4.06 (m, 1 H), 4.03–3.98 (m, 1H), 
3.23–3.17 (m, 1H), 2.90–2.76 (m, 2H), 1.78–1.71 (m, 1H), 0.98–0.93 (m, 2H), 0.76–0.72 (m, 2H). 13C NMR: 
(151 MHz, D2O): δ [ppm] = 148.9, 139.3, 138.5, 129.2, 68.3, 59.9, 45.5, 33.6, 22.9, 6.7, 6.7. 31P NMR: (243 MHz, 
D2O): − 10.73, − 10.91, − 23.27. HRMS (ESI−, m/z): calcd. for C14H21N6O10P3: 525.0459 [M-H]−, found 525.0360 
[M-H]−. IR (ATR): wavenumber [cm−1] = 2988, 2884, 1644, 1445, 1407, 1210, 1118, 891, 832, 484.
Synthesis of abacavir-5′-triphosphate and carbovir-5′-triphosphate. Carbovir 5′ -triphosphate 
(CBV-TP) was prepared similarly. Amounts used were: 308 mg (1.25 mmol) carbovir, 9.5 mL anhydrous pyri-
dine and 1.62 mL (1.62 mmol, 1.3 eq) of 1 M 5-chloro-cycloSaligenyl-phosphorcloridate solution (THF). The 
crude product was purified by flash column chromatography (CH2Cl2/CH3OH + 1% of acetic acid, 95:5 to 
90:10) to give 219 mg of the cycloSaligenyl-triester with minor impurities. In the second step 47.7 mg (106 μ mol) 
cycloSal-triester of carbovir in 1 mL dry DMF and 105 mg (159 μ mol) of bis-tetrabutylammonium hydrogen pyroph-
osphate in 0.8 mL DMF were reacted. After purification and freeze-drying 12.3 mg (22.1 μ mol) of the triphos-
phate was obtained as a colorless solid. 1H NMR: (600 MHz, D2O): δ [ppm] = 8.00 (s, 1H), 6.29–6.26 (m, 1H), 
5.94–5.92 (m, 1H), 5.54–5.49 (m, 1H), 4.08–3.98 (m, 2 H), 3.23–3.17 (m, 1H), 2.85–2.77 (m, 1H), 1.78–1.71 (m, 
1H). 13C NMR: (151 MHz, D2O): δ [ppm] = 158.6, 153.7, 151.0, 138.4, 138.3, 129.3, 115.2, 68.6, 60.1, 45.4, 33.8. 31P 
NMR: (243 MHz, D2O): − 10.87, − 10.98, − 23.31. HRMS (ESI−, m/z): calcd. for C11H16N5O11P3: 485.9986 [M-H]−, 
found 486.0020 [M-H]−. IR (ATR): wavenumber [cm−1] = 2988, 1686, 1610 1407, 1214, 1056, 1004, 948, 893, 473.
Measurement of in vitro dNTP triphosphohydrolase activity. SAMHD1 hydrolysis, activation and 
inhibition by nucleotide analogues was quantified using a continuous coupled assay employing the fluorescent 
phosphate biosensor MDCC-PBP to measure phosphate release from combined SAMHD1 triphosphohydrolase 
and S. cerevisiae Ppx1 exopolyphosphatase activity, described previously21. SAMHD1 and Ppx1 were expressed 
as strep-tagged fusion proteins and purified as described previously19,21. Didanosine triphosphate (ddI-TP) and 
dideoxy ATP (ddATP) were from Trilink Biotechnologies, Stavudine triphosphate (d4T-TP) was from Jena 
biosciences and Chemcyte. Abacavir triphosphate and Carbovir triphosphate were chemically synthesised in 
house from abacavir and carbovir as described above. Experiments were performed in 20 μ L reaction volumes 
in 384-well low-protein-binding microplates (Corning, USA). In typical experiments, solutions containing 
SAMHD1, Ppx1, MDCC-PBP and activator (GTP, ddI-TP or d4T-TP), or activator plus inhibitor, were incu-
bated for 5 min in assay buffer (20 mM Tris pH 8.0, 150 mM NaCl, 5 mM MgCl2 and 2 mM TCEP) at 25 °C before 
the reaction was initiated by the addition of substrate (TTP, ddI-TP or d4T-TP). The final concentrations were 
100 nM SAMHD1(115–626), 10 nM Ppx1, 2.5 μ M BSA, 40 μ M MDCC-PBP (80 μ M in ABC-TP and CBV-TP 
assays). Activator, substrate and inhibitor were added at concentrations described below. The fluorescence inten-
sity increase resulting from the phosphate-product binding to MDCC-PBP was recorded at 430 nm excitation and 
465 nm emission over 10–30 min in a Clariostar multiwell plate reader (BMG). Steady-state rates were obtained 
from the fluorescence time courses by fitting a linear function with maximal slope using the Mars software 
(BMG). Apparent dissociation constant of ddI-TP binding (KS), catalytic constant (kcat), maximal rate (kmax) and 
the ddI-TP concentration at half maximal activation (Ka) were determined by nonlinear least squares fitting using 
a Hill-function in the software package Grafit 7.0.3 (Erithacus software, UK). All measurements were performed 
at least in triplicate and data are represented as mean ± SEM.
Cell lines and reagents. Cell lines were obtained from the Programme EVA Centre for AIDS Reagents 
and tested free for mycoplasma contamination. Jurkat74, H975, U93776 and THP-1 cells77 were maintained in 
RPMI-1640 medium containing [L]-glutamine (Life Technologies), supplemented with heat-inactivated 10% 
foetal bovine serum (Labtech), 100 U penicillin-G/mL and 10 μ g streptomycin/mL. 293T cells were maintained 
in DMEM medium containing [D]-glucose, [L]-glutamine and sodium pyruvate (Life Technologies), supple-
mented with 10% foetal bovine serum (Labtech), 100 U penicillin-G/mL and 10 μ g streptomycin/mL. ACV 
and GCV were from Sequoia Research products (UK), CFB from Sigma-Aldrich (USA), d4T from Santa Cruz 
Biotechnology (USA), ddI and ABC from Stratech Scientific (UK), and Nevirapine (NVP) and Raltegravir (RAL) 
from Cayman Chemical (USA). All compounds were prepared at 100 mM in dimethyl sulphoxide and stored 
at − 20 °C until use.
Virus production. SAMHD1 and HIV-2 Vpx DNA sequences were inserted into pLGatewayIeYFP78. The 
active site mutation HD206-7AA was created by PCR-based site-directed mutagenesis (QuickChange-II XL, 
Agilent). Virus-like particles (VLPs) were produced by co-transfection of pVSV-G79, pKB480 and the pLGate-
wayIeYFP plasmids (SAMHD1, HD206-7AA or Vpx) into 293T cells and harvesting 48 h after transfection. 
HIV-1-GFP was made by co-transfection of pVSV-G, p8.9181 and pCSGW-GFP82. Viruses were titrated in U937 
cells and stocks stored at − 80 °C until use.
Cytotoxicity assays. H9, Jurkat and undifferentiated U937 and THP-1 (PMA−) cells (6 × 105 cells/mL) 
were treated with increasing concentrations of nucleoside analogues (0–200 μ M; except CFB, 0–1.6 μ M) and 
incubated at 37 °C in 5% CO2 for 48 h. Medium was then replaced and cells were further incubated for 72 h. 
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Non-dividing U937 and THP-1 (PMA+) cells (6 × 105 cells/mL) were differentiated by addition of 100 nM 
phorbol-12-myristate-13-acetate (PMA+) for 48 h and then treated with increasing concentrations of nucleoside 
analogues as described above. The percentage of live cells was determined by flow cytometry using Live/Dead 
fixable blue-fluorescent dyes (Invitrogen) and a Fortessa X20 analyser (BD Biosciences). Data were analysed using 
the FlowJo software suite.
Antiviral assays. H9 and Jurkat cells (6 × 105 cells/mL) were treated with increasing concentrations of 
nucleoside analogues (0–200 μ M; except CFB, 0–1.6 μ M) and incubated for 4 h at 37 °C in 5% CO2. Cells were 
then infected with HIV-1-GFP by spinoculation at 800 × g for 90 min in the presence of 1 μ g/mL polybrene, and 
further incubated at 37 °C in 5% CO2 for 72 h. Undifferentiated U937 and THP-1 (PMA−) cells (6 × 105 cells/
mL) were treated with increasing concentrations of nucleoside analogues (0–200 μ M; except CFB, 0–1.6 μ M) and 
incubated at 37 °C in 5% CO2 for 48 h. Cells were then infected with HIV-1-GFP by spinoculation at 800 × g for 
90 min in the presence of 1 μ g/mL polybrene, and further incubated at 37 °C in 5% CO2 for 72 h. Non-dividing 
U937 and THP-1 (PMA+) cells (6 × 105 cells/mL) were differentiated by addition of 100 nM PMA (PMA+) for 
48 h and treated with increasing concentrations of nucleoside analogues as described above. Cells were then 
infected with HIV-1-GFP in the presence of 1 μ g/mL polybrene and further incubated at 37 °C in 5% CO2 for 72 h. 
The percentage of GFP+cells was determined by one-colour flow cytometry using a Fortessa X20 analyser (BD 
Biosciences) and the data analysed using the FlowJo software suite.
Antiviral assays were further performed in monocytoid cells transduced with YFP-expressing VLPs con-
taining WT SAMHD1, HD206-7AA or Vpx. Briefly, U937 cells (6 × 105 cells/mL) were transduced with WT 
SAMHD1-YFP or HD206-7AA-YFP VLPs by spinoculation at 800 × g for 90 min in the presence of 1 μ g/mL 
polybrene. Similarly, THP-1 cells (6 × 105 cells/mL) were transduced with Vpx-YFP VLPs by spinoculation at 
800 × g for 90 min in the presence of 1 μ g/mL polybrene. Cells were incubated at 37 °C in 5% CO2 and after 72 h, 
PMA+ cells (6 × 105 cells/mL) were treated with 100 nM PMA and PMA− cells (7.5 × 104 cells/mL) were left 
untreated. Cells were then incubated at 37 °C in 5% CO2 for 48 h. Nucleoside analogues were added at increasing 
concentrations (0–200 μ M; except CFB, 0–1.6 μ M) and cells were further incubated for 48 h. PMA− cells were 
then infected with HIV-1-GFP by spinoculation at 800 × g for 90 min in the presence of 1 μ g/mL polybrene, 
PMA+ cells were infected with HIV-1-GFP in the presence of 1 μ g/mL polybrene only. Cells were incubated 
for 72 h at 37 °C in 5% CO2 and then analysed by two-colour flow cytometry using a Fortessa X20 analyser (BD 
Biosciences). Data were analysed using the FlowJo software suite.
Statistical analysis. The cytotoxic concentration of nucleoside analogue that inhibits cell viability by 50% 
(CC50) and the effective concentration of nucleoside analogue that inhibits infection of cells by 50% (EC50) were 
calculated for each independent experiment by non-linear regression using GraphPad Prism v6.00 for Windows 
(GraphPad Software, San Diego, CA). Non-ambiguous values were subjected to a replicate test to calculate confi-
dence intervals of 95% (95% CI). CC50 and EC50 values were determined for at least two independent experiments 
for each nucleoside analogue and a selectivity index (SI) also calculated, (SI = CC50/EC50). EC50 values for each 
replicate were used to perform an unpaired two-tailed t-test to determine significant differences between U937 
cells expressing SAMHD1 wt or HD206-7AA mutant and THP-1 cells expressing Vpx or untransduced cells. 
P values of < 0.005 were considered statistically significant.
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